ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LYEL vs BIOA // FORWARD P/E MULTIPLE

Lyell Immunopharma Inc. (NASDAQ) VS. BioAge Labs Inc. (NASDAQ) • 15-METRIC TALLY: LYEL 3 — BIOA 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LYEL VS. BIOA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LYEL BIOA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -41.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.66 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 LYEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 63.5 44.6 +18.90 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $277.0M $272.6M $4.4M LYEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LYEL REV BIOA REV LYEL GROSS % BIOA GROSS % LYEL FCF BIOA FCF
FY 2025 $36.0K $9.0M — — -$150.8M -$82.3M
FY 2024 $61.0K $0 — — -$162.9M -$51.9M
FY 2023 $130.0K $0 — — -$163.7M -$37.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LYEL // BETA —
BIOA // BETA —